drugset / Trial / NCT02358018

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

NCT02358018

Expanded access No longer available Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan, instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor. 68Ga-DOTATOC is an improved imaging agent being routinely used in many centers outside the USA, with better tumor detection than with OctreoScan.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATOC Peptide 10 ug Intravenous
Subject 68Ga-DOTATOC Peptide 50 ug Intravenous
Subject 68Ga-DOTATOC Peptide 111 mbq Intravenous
Subject 68Ga-DOTATOC Peptide 203.5 mbq Intravenous